PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092704
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092704
Negative Pressure Wound Therapy Market size was valued at US$ 3,105.6 Million in 2025, expanding at a CAGR of 7.7% from 2026 to 2033.
The negative pressure wound therapy market is expanding as hospitals and healthcare systems are seeking ways to care wounds. This is a concern because many people have chronic and surgical wounds. The International Diabetes Federation states that, over 589 million adults had diabetes worldwide in 2024. This indicates more people are developing foot ulcers and requires specialized care for their wounds. The World Health Organization predicts that many people will be sixty years old or older, by 2030. This means we will observe pressure injuries and venous leg ulcers. These issues are arising due to the changes in the world population is changing. Therefore, negative pressure wound therapy is increasingly needed in hospitals and other healthcare settings.
Negative Pressure Wound Therapy Market- Market Dynamics
Shift Toward Portable and Single-Use NPWT Devices in Home Healthcare Settings
Healthcare providers are using portable and disposable Negative Pressure Wound Therapy devices more. This is because people are receiving treatment at home and recovering as outpatients. Portable Negative Pressure Wound Therapy systems are very helpful because they allow people leave the hospital sooner. They also make it easier for individual to move around and care for their wounds. This makes them ideal for those recovering from surgery and for people with wounds.
The International Diabetes Federation states that, 589 million adults will have diabetes worldwide in 2024. The World Health Organization predicts that, there will be more elderly individuals, which will mean more chronic wounds that need to be cared of for long-term. Therefore, companies that manufacture Negative Pressure Wound Therapy devices are creating portable systems with quieter pumps and simpler dressings. They are also developing systems that people can use at home.
The Global Negative Pressure Wound Therapy Market is segmented on the basis of Product Type, Wound Type, Therapy Mode, End User, and Region.
By Product Type, conventional/standalone NPWT devices accounted for the largest market share in 2025, driven by their widespread adoption in hospitals for the treatment of complex acute and chronic wounds. These systems remain the standard of care due to their proven clinical effectiveness and extensive use in advanced wound management. In July 2024, AOTI received U.S. FDA clearance to expand the home-care indication for its NEXA Negative Pressure Wound Therapy System, supporting broader adoption across acute, extended, and home healthcare settings. Meanwhile, portable NPWT devices are gaining traction owing to improved patient mobility and shorter hospital stays.
Negative Pressure Wound Therapy Market- Geographical Insights
The companies that make Negative Pressure Wound Therapy systems are helping to make North America the leader in this market. The region is also home to companies like Solventum, Smith & Nephew and Cardinal Health. These companies are constantly developing Negative Pressure Wound Therapy systems that are approved by the FDA and adding new products to their lines of advanced wound care.
The Centers for Disease Control and Prevention state that, more than 38 million people in the United States have diabetes. This means they are likely to develop foot ulcers that require special care. The Agency for Healthcare Research and Quality reports that, about 2.5 million patients acquire pressure injuries every year in hospitals in the U.S. These injuries result in approximately 60,000 deaths annually. The number of people getting sick, good insurance coverage, new products being developed, and the amount of money being spent on healthcare make North America the largest market for Negative Pressure Wound Therapy.
The negative pressure wound therapy market is moderately consolidated, with leading companies, including Solventum, Smith & Nephew ConvaTec, Molnlycke Health Care, Cardinal Health, Paul Hartmann AG and Medela are trying to sell products that people can use at home. Negative pressure wound therapy systems are getting smaller and easier to use so people can take them home from the hospital. This is a change from the old systems that were only used in hospitals. The US Food and Drug Administration or FDA states that, negative pressure wound therapy systems are considered Class II devices. This means that companies have to obtain permission called 510(k) clearance before they can start selling these systems.
The Centers for Disease Control and Prevention or CDC states that, over 38 million Americans have diabetes. The Agency for Healthcare Research and Quality, or AHRQ states that, about 2.5 million people get pressure injuries every year in US hospitals. The government spends a lot of money, over 28 billion dollars, on wound care every year. Companies that make pressure wound therapy products are trying to show that their products are effective and can help people heal faster. They want to ensure that insurance companies will pay for these products and that hospitals will use them.
In August 2024, Guard Medical got approval from the FDA for sizes of its NPSeal surgical dressing. The new sizes go up to 25 cm. This helps with surgical incisions. Guard Medicals NPSeal dressing is used for NPWT.
In 2024, Solventum (formerly 3M Health Care) Continued expansion of its advanced wound care portfolio following its separation from 3M, strengthening focus on NPWT and surgical wound management.